TY  - JOUR
AU  - Đurić, Petar
AU  - Dimković, Nada
AU  - Schlieper, Georg
AU  - Đurić, Živka
AU  - Pantelić, Milan
AU  - Mitrović, Milica
AU  - Janković, Aleksandar N.
AU  - Milanov, Marko
AU  - Kuzmanović-Pfićer, Jovana
AU  - Floege, Juergen
PY  - 2020
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2514
AB  - Background. Sodium thiosulphate (NaTS) is mostly used in haemodialysis (HD) patients with calcific uraemic arteriolopathy. This double-blind, randomized, placebo-controlled study assessed the effect of NaTS on progression of cardiovascular calcifications in HD patients. Methods. From 65 screened patients, we recruited 60 patients with an abdominal aorta Agatston calcification score >= 100. Thirty patients were randomized to receive NaTS 25 g/1.73m(2) and 30 patients to receive 100mL of 0.9% sodium chloride intravenously during the last 15 min of HD over a period of 6 months. The primary endpoint was the absolute change of the abdominal aortic calcification score. Results. The abdominal aortic calcification score and calcification volume of the abdominal aorta increased similarly in both treatment groups during the trial. As compared with the saline group, patients receiving NaTS exhibited a reduction of their iliac artery calcification score (-137 +/- 641 versus 245 +/- 755; P = 0.049), reduced pulse wave velocity (9.6 +/- 2.7 versus 11.4 +/- 3.6; P = 0.000) and a lower carotid intima-media thickness (0.77 +/- 0.1 versus 0.83 +/- 00.17; P = .033) and had better preservation of echocardiographic parameters of left ventricular hypertrophy. No patient of the NaTS group developed new cardiac valve calcifications during the trial as compared with 8 of 29 patients in the saline group. By univariate analysis, NaTS therapy was the only predictor of not developing new valvular calcifications. No adverse events possibly related to NaTS infusion were noted. Conclusions. While NaTS failed to retard abdominal aortic calcification progress, it positively affected calcification progress in iliac arteries and heart valves as well as several other cardiovascular functional parameters.
PB  - Oxford Univ Press, Oxford
T2  - Nephrology Dialysis Transplantation
T1  - Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study
VL  - 35
IS  - 1
SP  - 162
EP  - 169
DO  - 10.1093/ndt/gfz204
ER  - 

@article{
author = "Đurić, Petar and Dimković, Nada and Schlieper, Georg and Đurić, Živka and Pantelić, Milan and Mitrović, Milica and Janković, Aleksandar N. and Milanov, Marko and Kuzmanović-Pfićer, Jovana and Floege, Juergen",
year = "2020",
abstract = "Background. Sodium thiosulphate (NaTS) is mostly used in haemodialysis (HD) patients with calcific uraemic arteriolopathy. This double-blind, randomized, placebo-controlled study assessed the effect of NaTS on progression of cardiovascular calcifications in HD patients. Methods. From 65 screened patients, we recruited 60 patients with an abdominal aorta Agatston calcification score >= 100. Thirty patients were randomized to receive NaTS 25 g/1.73m(2) and 30 patients to receive 100mL of 0.9% sodium chloride intravenously during the last 15 min of HD over a period of 6 months. The primary endpoint was the absolute change of the abdominal aortic calcification score. Results. The abdominal aortic calcification score and calcification volume of the abdominal aorta increased similarly in both treatment groups during the trial. As compared with the saline group, patients receiving NaTS exhibited a reduction of their iliac artery calcification score (-137 +/- 641 versus 245 +/- 755; P = 0.049), reduced pulse wave velocity (9.6 +/- 2.7 versus 11.4 +/- 3.6; P = 0.000) and a lower carotid intima-media thickness (0.77 +/- 0.1 versus 0.83 +/- 00.17; P = .033) and had better preservation of echocardiographic parameters of left ventricular hypertrophy. No patient of the NaTS group developed new cardiac valve calcifications during the trial as compared with 8 of 29 patients in the saline group. By univariate analysis, NaTS therapy was the only predictor of not developing new valvular calcifications. No adverse events possibly related to NaTS infusion were noted. Conclusions. While NaTS failed to retard abdominal aortic calcification progress, it positively affected calcification progress in iliac arteries and heart valves as well as several other cardiovascular functional parameters.",
publisher = "Oxford Univ Press, Oxford",
journal = "Nephrology Dialysis Transplantation",
title = "Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study",
volume = "35",
number = "1",
pages = "162-169",
doi = "10.1093/ndt/gfz204"
}

Đurić, P., Dimković, N., Schlieper, G., Đurić, Ž., Pantelić, M., Mitrović, M., Janković, A. N., Milanov, M., Kuzmanović-Pfićer, J.,& Floege, J.. (2020). Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. in Nephrology Dialysis Transplantation
Oxford Univ Press, Oxford., 35(1), 162-169.
https://doi.org/10.1093/ndt/gfz204

Đurić P, Dimković N, Schlieper G, Đurić Ž, Pantelić M, Mitrović M, Janković AN, Milanov M, Kuzmanović-Pfićer J, Floege J. Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study. in Nephrology Dialysis Transplantation. 2020;35(1):162-169.
doi:10.1093/ndt/gfz204 .

Đurić, Petar, Dimković, Nada, Schlieper, Georg, Đurić, Živka, Pantelić, Milan, Mitrović, Milica, Janković, Aleksandar N., Milanov, Marko, Kuzmanović-Pfićer, Jovana, Floege, Juergen, "Sodium thiosulphate and progression of vascular calcification in end-stage renal disease patients: a double-blind, randomized, placebo-controlled study" in Nephrology Dialysis Transplantation, 35, no. 1 (2020):162-169,
https://doi.org/10.1093/ndt/gfz204 . .

TY  - JOUR
AU  - Ašćerić, Radislav
AU  - Dimković, Nada
AU  - Trajković, Goran Z.
AU  - Ristić, Biljana S.
AU  - Janković, Aleksandar N.
AU  - Đurić, Petar
AU  - Ilijevski, Nenad S.
PY  - 2019
UR  - https://smile.stomf.bg.ac.rs/handle/123456789/2410
AB  - BackgroundPeripheral arterial disease (PAD) is common in patients with end-stage renal disease on hemodialysis, but is frequently underdiagnosed. The risk factors for PAD are well known within the general population, but they differ somewhat in hemodialysis patients. This study aimed to determine the prevalence of PAD and its risk factors in patients on hemodialysis.MethodsThis cross-sectional study included 156 hemodialysis patients. Comorbidities and laboratory parameters were analyzed. Following clinical examinations, the ankle-brachial index was measured in all patients. PAD was diagnosed based on the clinical findings, ankle-brachial index  lt 0.9, and PAD symptoms.ResultsPAD was present in 55 of 156 (35.3%; 95% CI, 27.7-42.8%) patients. The patients with PAD were significantly older (6710years vs. 62 +/- 11years, p=0.014), more likely to have diabetes mellitus (p=0.022), and anemia (p=0.042), and had significantly lower serum albumin (p=0.005), total cholesterol (p=0.024), and iron (p=0.004) levels, higher glucose (p=0.002) and C-reactive protein (p lt 0.001) levels, and lower dialysis adequacies (p=0.040) than the patients without PAD. Multivariate analysis showed higher C-reactive protein level (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.00-1.06; p=0.030), vascular access by Hickman catheter (OR, 4.66; 95% CI, 1.03-21.0; p=0.045), and symptoms of PAD (OR, 5.20; 95% CI, 2.60-10.4; p lt 0.001) as independent factors associated with PAD in hemodialysis patients.ConclusionThe prevalence of PAD was high among patients with end-stage renal disease on hemodialysis. Symptoms of PAD, higher C-reactive protein levels, and Hickman vascular access were independent predictors of PAD in patients on hemodialysis.
PB  - BMC, LONDON
T2  - BMC Nephrology
T1  - Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study
VL  - 20
DO  - 10.1186/s12882-019-1468-x
ER  - 

@article{
author = "Ašćerić, Radislav and Dimković, Nada and Trajković, Goran Z. and Ristić, Biljana S. and Janković, Aleksandar N. and Đurić, Petar and Ilijevski, Nenad S.",
year = "2019",
abstract = "BackgroundPeripheral arterial disease (PAD) is common in patients with end-stage renal disease on hemodialysis, but is frequently underdiagnosed. The risk factors for PAD are well known within the general population, but they differ somewhat in hemodialysis patients. This study aimed to determine the prevalence of PAD and its risk factors in patients on hemodialysis.MethodsThis cross-sectional study included 156 hemodialysis patients. Comorbidities and laboratory parameters were analyzed. Following clinical examinations, the ankle-brachial index was measured in all patients. PAD was diagnosed based on the clinical findings, ankle-brachial index  lt 0.9, and PAD symptoms.ResultsPAD was present in 55 of 156 (35.3%; 95% CI, 27.7-42.8%) patients. The patients with PAD were significantly older (6710years vs. 62 +/- 11years, p=0.014), more likely to have diabetes mellitus (p=0.022), and anemia (p=0.042), and had significantly lower serum albumin (p=0.005), total cholesterol (p=0.024), and iron (p=0.004) levels, higher glucose (p=0.002) and C-reactive protein (p lt 0.001) levels, and lower dialysis adequacies (p=0.040) than the patients without PAD. Multivariate analysis showed higher C-reactive protein level (odds ratio [OR], 1.03; 95% confidence interval [CI], 1.00-1.06; p=0.030), vascular access by Hickman catheter (OR, 4.66; 95% CI, 1.03-21.0; p=0.045), and symptoms of PAD (OR, 5.20; 95% CI, 2.60-10.4; p lt 0.001) as independent factors associated with PAD in hemodialysis patients.ConclusionThe prevalence of PAD was high among patients with end-stage renal disease on hemodialysis. Symptoms of PAD, higher C-reactive protein levels, and Hickman vascular access were independent predictors of PAD in patients on hemodialysis.",
publisher = "BMC, LONDON",
journal = "BMC Nephrology",
title = "Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study",
volume = "20",
doi = "10.1186/s12882-019-1468-x"
}

Ašćerić, R., Dimković, N., Trajković, G. Z., Ristić, B. S., Janković, A. N., Đurić, P.,& Ilijevski, N. S.. (2019). Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study. in BMC Nephrology
BMC, LONDON., 20.
https://doi.org/10.1186/s12882-019-1468-x

Ašćerić R, Dimković N, Trajković GZ, Ristić BS, Janković AN, Đurić P, Ilijevski NS. Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study. in BMC Nephrology. 2019;20.
doi:10.1186/s12882-019-1468-x .

Ašćerić, Radislav, Dimković, Nada, Trajković, Goran Z., Ristić, Biljana S., Janković, Aleksandar N., Đurić, Petar, Ilijevski, Nenad S., "Prevalence, clinical characteristics, and predictors of peripheral arterial disease in hemodialysis patients: a cross-sectional study" in BMC Nephrology, 20 (2019),
https://doi.org/10.1186/s12882-019-1468-x . .